Condensed Consolidated Statements Of Stockholders' Equity - USD ($) $ in Thousands	Total	Hurdle Share Option Plan [Member]	Common Stock [Member]	Common Stock [Member] Hurdle Share Option Plan [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Hurdle Share Option Plan [Member]	Share Subscriptions Receivable [Member]	Share Subscriptions Receivable [Member] Hurdle Share Option Plan [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Other Comprehensive Income (Loss) [Member] Hurdle Share Option Plan [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member] Hurdle Share Option Plan [Member]	Total Stockholders' Equity Attributable to ATAI Life Sciences N.V. Stockholders [Member]	Total Stockholders' Equity Attributable to ATAI Life Sciences N.V. Stockholders [Member] Hurdle Share Option Plan [Member]	Noncontrolling Interests [Member]	Noncontrolling Interests [Member] Hurdle Share Option Plan [Member]
Beginning Balance at Dec. 31, 2020	$ 95,368		$ 13,372		$ 261,626		$ 0		$ 5,819		$ (189,995)		$ 90,822		$ 4,546
Beginning Balance, Shares at Dec. 31, 2020			114,735,712
Issuance of common shares, net of issuance costs	23,510	$ 0	$ 1,881	$ 0	162,497	$ 0	(140,868)	$ 0	0	$ 0	0	$ 0	23,510	$ 0	0	$ 0
Issuance of common shares, net of issuance costs ,Shares			15,552,688
Issuance of common shares under the Hurdle Share Option Plan (see Note 12)				7,281,376
Issuance of noncontrolling interest	885		$ 0		0		0		0		0		0		885
Stock-based compensation expense	212		0		212		0		0		0		212		0
Foreign currency translation adjustment, net of tax	(4,026)		0		0		0		(3,842)		0		(3,842)		(184)
Net income (loss)	4,044		$ 0		0		0		0		688		688		3,356
Ending Balance, Shares at Mar. 31, 2021			137,569,776
Ending Balance at Mar. 31, 2021	119,993		$ 15,253		424,335		$ (140,868)		1,977		(189,307)		111,390		8,603
Beginning Balance at Dec. 31, 2021	385,959		$ 18,002		725,045				(8,336)		(357,803)		376,908		9,051
Beginning Balance, Shares at Dec. 31, 2021			160,677,001
Issuance of shares upon exercise of stock options, shares			42,827
Issuance of shares upon exercise of stock options	132		$ 5		127				0		0		132		0
Stock-based compensation expense	10,208		0		10,208				0		0		10,208		0
Foreign currency translation adjustment, net of tax	(4,384)		0		0				(4,373)		0		(4,373)		(11)
Net income (loss)	(37,558)		$ 0		0				0		(36,869)		(36,869)		(689)
Ending Balance, Shares at Mar. 31, 2022			160,719,828
Ending Balance at Mar. 31, 2022	$ 354,357		$ 18,007		$ 735,380				$ (12,709)		$ (394,672)		$ 346,006		$ 8,351